Metabolic dysfunction-associated steatotic liver disease (MASLD), is a chronic, asymptomatic, progressive condition affecting about 38% of the global population. It is characterized by substantial interpatient variability in disease severity and outcomes. MASLD is caused by a build-up of fat in the liver and includes a range of disease states, from isolated lipid accumulation or steatosis (metabolic dysfunctionassociated steatotic liver, MASL) to its active inflammatory form, metabolic dysfunction-associated steatohepatitis (MASH).
Some points should be noted while setting the goal for diagnostic tests for advanced liver disease at the primary and secondary healthcare levels, such as:
Diagnosis and identification of the patients at different stages of the disease can be done with the help of biomarkers, which can be categorized into two groups, i.e., indirect and direct serum biomarkers and imaging biomarkers.
For example, in the enhanced liver fibrosis (ELF) test in MASLD, three direct markers of fibrosis are combined, such as procollagen III N-terminal peptide, hyaluronic acid and tissue inhibitor of metaproteinase 1 (TIMP1).
Some other key biomarker strategies that can help in diagnosing are:
Subscribe To Our Newsletter
Filter out the noise and nurture your inbox with health and wellness advice that's inclusive and rooted in medical expertise.
Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks
Please update your details